The Laser You Can't Afford Is the One Sitting Idle

Someone posted a question to r/Esthetics last summer asking how anyone affords these machines. It drew 33 upvotes and 30 comments. I went through the whole thread looking for a number. There wasn't one. There were financing companies, there were opinions about which rep lies least, there was a person who said their device paid for itself in eight months without saying what it cost or what they charged. Thirty comments about a six-figure decision and not one worked example.

That is not a Reddit problem. That is the state of the market. Aesthetic device purchases are among the largest capital decisions an independent practice makes, and they are routinely made on a conference-floor demo, a financing sheet, and a payback number the rep supplied.

The payback number is usually not wrong. It is incomplete, and the part it leaves out is the part that costs you.

The math everyone does at the booth

The standard calculation goes like this. The device costs some amount. A treatment sells for some amount. Divide, add a cushion, and you get treatments-per-month to break even. If that number looks achievable, you sign.

Here is the number that calculation omits. Buyers who acquire aesthetic practices do not model a device as a one-time purchase. They model it as a recurring line. In diligence, replacement capital expenditure over the first three years of ownership is typically modeled at 100 to 250 thousand dollars per treatment room, according to CT Acquisitions' 2026 med spa valuation guide, which draws on FOCUS Investment Banking, BizBuySell, and AmSpa.

Run that division, because the derivation is more useful than the band. A hundred thousand dollars over three years is about $641 a week per treatment room. At the top of the range it is roughly $1,603 a week. That is the carrying cost of staying current, per room, before you have paid for a single consumable, a single provider hour, or the room itself.

Your booth math asked whether one device pays for itself. The real question is whether the room generates enough contribution to fund a device every three years, forever, because that is what the category actually requires.

I looked for a defensible published benchmark for contribution margin on device treatments in this vertical. I did not find one I would put my name on. Every figure I could trace ran back to a manufacturer or a vendor quoting itself. So I am not going to hand you a margin assumption. I am going to tell you that the denominator you need is one only your own books can produce, and that the absence of a credible industry number is itself worth knowing before you take a rep's.

The manufacturer's margin is public. Yours is not.

Here is an asymmetry that almost no owner uses, and it costs nothing to look up.

InMode makes Morpheus8 and BodyTite, two of the devices CT Acquisitions names as the current generation under diligence scrutiny, alongside CoolSculpting Elite, Sciton's Joule and BBL, Cynosure's Elite iQ, and Alma's Harmony XL Pro. InMode is publicly traded, so its financials are audited and filed. Company-wide gross margin was 78.53% in fiscal 2025, down from 85.01% in fiscal 2021.

Sit with that. On a company-wide basis, roughly four of every five dollars you hand a device manufacturer is gross margin to them. That is not an accusation, it is a business model, and it is the same model as any capital equipment maker. But it tells you something practical about the negotiation you are in: there is room in that price, and the rep's payback math is built to keep you from looking for it.

The second thing in those filings is more interesting, and it is the part I would want an owner to sit with before signing anything. InMode's revenue fell from $492.05 million in fiscal 2023 to $370.5 million in fiscal 2025. That is a decline of about 25% in two years, with gross margin compressing more than six points over the same stretch.

Device makers sell to practices. When device maker revenue falls by a quarter, practices are buying fewer devices. You are being pitched into a market that is contracting, by a company whose margin is under pressure, which is precisely when the financing terms get most attractive and the payback math gets most optimistic.

That same contraction shows up on the other side of the trade. The Reddit thread that has stayed with me was not the one asking how people afford these machines. It was a shorter one, from an owner closing shop, asking where to sell the equipment.

What the device does to your exit

This is the part that does not appear in any payback calculation, and it is the one I would put in front of any owner within five years of selling.

Practices are not valued as a pile of equipment plus a patient list. They are valued on a multiple of earnings, and the multiple moves with the quality of those earnings. On that dimension, device revenue is penalized. Buyers apply a discount of 0.5x to 1.0x turns to device-heavy practices compared with injectables-heavy peers, per CT Acquisitions. The stated reasons are that device revenue tracks consumer discretionary cycles more closely, that it carries ongoing consumable costs, and that it forces continuous reinvestment as new platforms arrive.

Half a turn to a full turn. On a practice earning several hundred thousand dollars in adjusted profit, that is real money, and it is money you lose at closing for a decision you made years earlier on a conference floor.

There is a trap on the other side too, and it catches the disciplined owner rather than the impulsive one. If you buy a device and hold it until it is fully depreciated, your books start to look excellent. No depreciation charge, revenue still flowing, margins apparently strong. CT's diligence teams treat exactly that pattern as a warning: a fully depreciated fleet means reported earnings overstate the go-forward economics, because the buyer has to fund replacement immediately. The better your aging equipment makes your profit and loss look, the harder the diligence adjustment lands.

So the device costs you three times. Once when you buy it. Again every three years to stay current. And a third time as a haircut on the multiple, whether you replaced it or not.

What to actually do before you sign

Not ten things. Four, in order, and they take an afternoon.

First, compute the per-room carrying cost. Take your treatment rooms, multiply by the $100,000 to $250,000 three-year replacement band, divide by 156 weeks. That is the number the device has to clear before it has done anything for you. If your practice cannot fund that from contribution today, an additional device does not fix it.

Second, get your own contribution margin per treatment from your own books, not from the rep. Treatment price, minus consumables, minus the loaded provider hour, minus the room hour. No industry benchmark substitutes for this, because none of the published ones survive tracing.

Third, ask the rep for the device's installed base and unit trend in your metro, in writing. If they will not put it in writing, you have learned something. The manufacturer's public filings will tell you the direction of their overall business for free.

Fourth, and this is the one owners skip: price the alternative. CT's data has practices in growth mode spending 8 to 15 percent of revenue on marketing, against 5 to 8 percent at maturity. Before committing $150,000 of capital plus a three-year replacement obligation to a device, run the same money through demand generation for the services you already deliver, at the treatment volumes you already have, and compare. Sometimes the device wins. But the comparison almost never gets made, and a capital decision made without its alternative priced is not a decision. It is a purchase.

Sources. Replacement capital expenditure per treatment room, the 0.5x to 1.0x device-heavy multiple discount, the fully-depreciated-fleet diligence adjustment, the named current-generation device list, and the marketing-spend bands are from CT Acquisitions' Med Spa and Medical Aesthetic M&A Multiples Report 2026, published July 2026, which cites FOCUS Investment Banking, BizBuySell, Scope Research, and AmSpa as upstream sources. InMode revenue and gross margin figures are from the company's reported fiscal 2021 through fiscal 2025 financials. The r/Esthetics and r/medspa observations were collected on 2026-06-28 with subreddit, title, and score recorded; permalinks were not captured at collection time and Reddit was not reachable at the time of writing, so treat those two as illustrative of what owners are asking rather than as verifiable citations. The argument does not rest on them.

---

The honest summary is this. A device that runs constantly in a busy room can be a good investment. A device that runs four times a month is not a break-even that has not arrived yet, it is a permanent drag on the multiple you will eventually sell into. The question is never whether the machine works. It is whether your room is full enough to deserve it.

If the answer is that the room is not full, the constraint is demand, and buying capacity to serve demand you do not have is the most expensive way to discover that. Filling the room is the work GrowBien does, and it is the cheaper experiment to run first.